Investors have been flocking to biotech stocks this year, with the IBB, the ETF that tracks biotech stocks, making noteworthy gains. So far in 2015, several industries have either underperformed or provided mixed results, leading to a rather ho-hum showpiece for U.S. blue-chip indices.Biotech stocks, on the other hand, have consistently returned positive results in the markets over the past […]
Investors have been flocking to biotech stocks this year, with the IBB, the ETF that tracks biotech stocks, making noteworthy gains. So far in 2015, several industries have either underperformed or provided mixed results, leading to a rather ho-hum showpiece for U.S. blue-chip indices.Biotech stocks, on the other hand, have consistently returned positive results in the markets over the past […]
They say good things come in threes. If so, biotech companies could be in for not just another year of outperformance, but another decade. The first era of biotech was a building phase, when companies created their first blockbuster drugs. The second, current one, has resulted in a four-year rally that reflects the sector’s transition from a cluster of one-hit […]
Investors have been flocking to biotech stocks this year, with the IBB, the ETF that tracks biotech stocks, making noteworthy gains. So far in 2015, several industries have either underperformed or provided mixed results, leading to a rather ho-hum showpiece for U.S. blue-chip indices.Biotech stocks, on the other hand, have consistently returned positive results in the markets over the past […]
Related CLVSClovis Oncology Could Pass $100 By Year-End: Here’s WhyClovis Oncology Completes US, EU Regulatory Submissions for Rociletinib for Treatment of Advanced EGFR-Mutant T790M+ NSCLCClovis Oncology: Don’t Discount Rociletinib’s Chances Against AZD9291(Seeking Alpha)Related EPZMBenzinga’s Top DowngradesH.C. Wainwright Destroys Epizyme Price Target, Sees ‘No Material Value Drivers’A new report by Mizuho analyst Peter Lawson focuses on biotech stocks with major catalysts […]
Investors have been flocking to biotech stocks this year, with the IBB, the ETF that tracks biotech stocks, making noteworthy gains. So far in 2015, several industries have either underperformed or provided mixed results, leading to a rather ho-hum showpiece for U.S. blue-chip indices.Biotech stocks, on the other hand, have consistently returned positive results in the markets over the past […]
They say good things come in threes. If so, biotech companies could be in for not just another year of outperformance, but another decade. The first era of biotech was a building phase, when companies created their first blockbuster drugs. The second, current one, has resulted in a four-year rally that reflects the sector’s transition from a cluster of one-hit […]
If there is such a thing as a poster child for volatility in the stock market, the biotech sector would likely take top honors.Biotech stocks are unique. While stocks in other sectors are typically valued based on their past performance and future earnings potential, the majority of biotech stocks don’t have a cent in recurring revenue. Instead, biotech stocks are […]
Many individual investors have opted to invest in biotech ETFs and mutual funds. The XBI and SBIO funds have performed well because they focus more on small and mid-sized biotech companies. The IBB, which has emerged as something of a proxy for the industry for many investors, is weighted much more heavily to bigger, more proven biotech companies.The volatility of […]
Many individual investors have opted to invest in biotech ETFs and mutual funds. The XBI and SBIO funds have performed well because they focus more on small and mid-sized biotech companies. The IBB, which has emerged as something of a proxy for the industry for many investors, is weighted much more heavily to bigger, more proven biotech companies.The volatility of […]
